Glaukos (NYSE:GKOS) said today that it inked a licensing deal with Intratus for that company’s transdermal drug delivery platform for treating eye conditions.
San Diego-based Intratus developed cream-based drug formulations that are applied to the outer eyelid to treat conditions such as dry eye disease, glaucoma, allergy, blepharitis and conjunctivitis. The deal gives San Clemente, Calif.-based Glaukos exclusive rights to the technology for treating glaucoma and corneal disorders in return for an undisclosed amount.
“This licensing agreement adds a novel drug delivery platform using a differentiated, non-invasive transdermal approach to our expanding portfolio of sustained pharmaceutical systems,” president & CEO Thomas Burns said in prepared remarks. “Intratus’ proprietary transdermal drug delivery application is highly complementary to our expanding portfolio of sustained pharmaceutical systems and represents a synergistic fit with our glaucoma and corneal health R&D initiatives. With this agreement, we plan to build upon the promising development work Intratus has completed to advance this exciting new drug delivery approach into the appropriate clinical phases.”
“Intratus’ drug delivery platforms aim to provide an efficacious, safe and durable treatment option for ophthalmic diseases through a simple, non-invasive and patient-friendly method of application,” added Intratus co-founder & CEO Aaron Dyer and co-founder & CMO Dr. Padma Nanduri. “We believe Glaukos’ proven track record in pioneering new treatment paradigms makes them the perfect partner to help bring our novel treatment options, if approved, to patients and physicians in the most effective and timely manner possible.”
